Novartis’ Zykadia ASCEND-4 Study Close But No Cigar In NSCLC
The presentation of the full data from Novartis’ ASCEND-4 study of Zykadia show decent efficacy in first-line NSCLC but are unlikely to be enough to overcome doctors’ caution over its tolerability profile, especially with rival Alecensa snapping at its heels.
You may also be interested in...
Data from two studies confirm Alecensa's superiority over Pfizer's Xalkori and help Roche close the gap on Novartis' Zykadia.
The latest drug development news and highlights from our US FDA Performance Tracker.
Roche’s Alecensa gets EU nod for second-line use in ALK+ non-small cell lung cancer patients – but first-line data in 2017 will be vital.